Dr. Eliseo Oreste Salinas to Join Adolor Corporation as Senior Vice President Research & Development and Chief Medical Officer
11 April 2008 - 11:00PM
Business Wire
Adolor Corporation (Nasdaq:ADLR) announced today that Eliseo Oreste
Salinas, MD, MSc, will join Adolor as senior vice president
research and development and chief medical officer. Dr. Salinas
will commence his employment with Adolor on June 2, 2008 and will
report to Michael R. Dougherty, president & chief executive
officer, Adolor Corporation. �We are extremely pleased that Eliseo
will be joining the Adolor team,� said Mr. Dougherty. �His
extensive CNS research and clinical development experience will be
of tremendous benefit to Adolor as we advance our promising
portfolio of novel pain management programs.� Dr. Salinas has more
than fifteen years of pharmaceutical industry research experience.
Most recently, he has served as the executive vice president of
Global Research & Development and chief scientific officer for
Shire, Inc. Prior to joining Shire, Dr. Salinas served in several
senior management roles at Wyeth-Ayerst including vice president of
research for North and South America. He has published scientific
articles and abstracts worldwide in psychopharmacology. Dr. Salinas
earned his Doctorate of Medicine from the University of Buenos
Aires, Argentina and a Master in Pharmacology from the University
Paris, France where he also performed his residency in Psychiatry.
�Adolor presents an intriguing combination of later stage clinical
development programs and impressive early stage discovery
capabilities,� said Dr. Salinas. "I look forward to joining Adolor
and working with a truly outstanding research and development team.
� About Adolor Corporation Adolor Corporation (Nasdaq:ADLR) is a
biopharmaceutical company specializing in the discovery,
development and commercialization of novel prescription pain
management products. Adolor has two lead product candidates in
development: Entereg� (alvimopan) for the management of the
gastrointestinal side effects associated with opioid use; and,
novel Delta opioid receptor agonists for a variety of pain
indications. Adolor and GlaxoSmithKline are collaborating in the
worldwide development and commercialization of Entereg in multiple
indications. Adolor and Pfizer are collaborating in the worldwide
development and commercialization of two Delta agonists for pain.
Adolor also has a number of discovery research programs focused on
the identification of novel compounds for the treatment of pain. By
applying its knowledge and expertise in pain management, along with
ingenuity, Adolor is seeking to make a positive difference for
patients, caregivers and the medical community. For more
information, visit www.adolor.com. This release, and oral
statements made with respect to information contained in this
release, constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact.
These statements are based upon management's current expectations
and are subject to risks and uncertainties, known and unknown,
which could cause actual results and developments to differ
materially from those expressed or implied in such statements. Such
known risks and uncertainties relate to, among other factors: the
risk that filing targets for regulatory filings are not met; the
costs, delays and uncertainties inherent in scientific research,
drug development, clinical trials and the regulatory approval
process; Adolor's history of operating losses since inception and
its need for additional funds to operate its business; Adolor's
reliance on its collaborators; market acceptance of Adolor's
products, if regulatory approval is achieved; reliance on third
party manufacturers; product liability claims; competition; and
securities litigation. Further information about these and other
relevant risks and uncertainties may be found in Adolor's Reports
on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission. Adolor urges you to carefully review and
consider the disclosures found in its filings which are available
in the SEC EDGAR database at http://www.sec.gov and from Adolor at
http://www.adolor.com. Given the uncertainties affecting
pharmaceutical companies in the development stage, you are
cautioned not to place undue reliance on any such forward-looking
statements, any of which may turn out to be wrong due to inaccurate
assumptions, unknown risks, uncertainties or other factors. Adolor
undertakes no obligation to (and expressly disclaims any such
obligation to) publicly update or revise the statements made herein
or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise.
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Adolor Corp. (MM) (NASDAQ): 0 recent articles
More Adolor Corporation News Articles